
InnoStar launches its 24,000 sqm Nantong Phase II Non-Clinical Evaluation Platform in China, featuring 130 animal rooms to ease capacity constraints and accelerate drug development.
InnoStar Nantong Facility Successfully Passed U.S. FDA GLP Inspection
Copyright © 2017-2021©Shanghai InnoStar Bio-tech Co., Ltd. All Rights Reserved. Created By VPABrand.com